Testing DT-101 against a placebo for major depressive disorder in adults
Tests whether DT-101 can treat major depressive disorder in adults.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
Key facts
- Where
- Kazanlak, Plovdiv, Sofia, and Vratsa, BulgariaSee the 4 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07300969, who can take part
Where in Bulgaria
- KazanlakKazanlak, BulgariaTaking people
- PlovdivPlovdiv, BulgariaTaking people
- SofiaSofia, BulgariaTaking people
- VratsaVratsa, BulgariaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Draig Therapeutics Ltd
- Trial code
- NCT07300969
- Record updated
- 8 October 2026
- Original description
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.Read full original descriptionShow less
A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)
The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.
Inclusion: The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent; Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent; Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).
Exclusion: History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening; Unstable medical condition or unstable chronic disease; History of seizure; Pregnant or breastfeeding or plans to become pregnant during the study; Significant neurological abnormality; In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.